Who are Hepa-B's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, Spikevax bivalent Original/Omicron BA.1, A second dose with an 1 year interval, FSME-Immune vaccination, bOPV (two dose).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hepa-b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Hepa-B — Competitive Intelligence Brief

Hepa-B (Hepa-B) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology / Infectious Disease.

marketed Vaccine Hepatitis B surface antigen (HBsAg) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Hepa-B (Hepa-B) — International Centre for Diarrhoeal Disease Research, Bangladesh. Hepa-B is a hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hepa-B TARGET	Hepa-B	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Vaccine	Hepatitis B surface antigen (HBsAg)
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Spikevax bivalent Original/Omicron BA.1	Spikevax bivalent Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
A second dose with an 1 year interval	A second dose with an 1 year interval	Shanghai Municipal Center for Disease Control and Prevention	marketed	vaccine
FSME-Immune vaccination	FSME-Immune vaccination	Medical University of Vienna	marketed	Inactivated viral vaccine	Tick-borne encephalitis virus (TBEV) envelope proteins
bOPV (two dose)	bOPV (two dose)	Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Poliovirus types 1 and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hepa-B — Competitive Intelligence Brief. https://druglandscape.com/ci/hepa-b. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab